Selective coronary angiography, percutaneous coronary intervention and asymptomatic peri-procedural myocardial injury.


Journal

Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia
ISSN: 1804-7521
Titre abrégé: Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub
Pays: Czech Republic
ID NLM: 101140142

Informations de publication

Date de publication:
Dec 2019
Historique:
received: 22 07 2018
accepted: 15 10 2018
pubmed: 7 11 2018
medline: 9 6 2020
entrez: 7 11 2018
Statut: ppublish

Résumé

While there have been a number of studies reporting the incidence and implications of elevated troponin levels after percutaneous coronary intervention (PCI), the body of information about the incidence, associations, and implications of elevated troponin levels following coronary angiography (CAG) is limited. A total of 220 consecutive patients with stable coronary artery disease or intermediate or low-risk acute coronary syndrome without persistent ST-segment elevation (NSTE-ACS) were included in our study. High-sensitivity cardiac troponin I (hs-cTnI) levels were measured before and after coronary angiography (CAG) in patients with or without PCI and correlated with a number of clinical variables. Hs-cTnI elevations above the 99 While an asymptomatic elevation of hs-cTnI is a common finding after PCI, it does occur, quite surprisingly, also after CAG. Despite contradictory views regarding the clinical relevance of asymptomatic post-procedural elevated hs-cTnI levels, it is generally believed that a mild elevation is not associated with an increased risk. Still, it may pose a diagnostic quandary following a successful interventional procedure and even more so after an uncomplicated CAG. Clinicaltrials.gov - NCT02960321.

Sections du résumé

BACKGROUND BACKGROUND
While there have been a number of studies reporting the incidence and implications of elevated troponin levels after percutaneous coronary intervention (PCI), the body of information about the incidence, associations, and implications of elevated troponin levels following coronary angiography (CAG) is limited.
MATERIALS AND METHODS METHODS
A total of 220 consecutive patients with stable coronary artery disease or intermediate or low-risk acute coronary syndrome without persistent ST-segment elevation (NSTE-ACS) were included in our study. High-sensitivity cardiac troponin I (hs-cTnI) levels were measured before and after coronary angiography (CAG) in patients with or without PCI and correlated with a number of clinical variables.
RESULTS RESULTS
Hs-cTnI elevations above the 99
CONCLUSION CONCLUSIONS
While an asymptomatic elevation of hs-cTnI is a common finding after PCI, it does occur, quite surprisingly, also after CAG. Despite contradictory views regarding the clinical relevance of asymptomatic post-procedural elevated hs-cTnI levels, it is generally believed that a mild elevation is not associated with an increased risk. Still, it may pose a diagnostic quandary following a successful interventional procedure and even more so after an uncomplicated CAG.
TRIAL REGISTRATION BACKGROUND
Clinicaltrials.gov - NCT02960321.

Identifiants

pubmed: 30398220
doi: 10.5507/bp.2018.066
doi:

Substances chimiques

Biomarkers 0
Troponin 0

Banques de données

ClinicalTrials.gov
['NCT02960321']

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

324-330

Auteurs

Martin Griva (M)

Cardiovascular Center for Adults, Tomas Bata Regional Hospital, Zlin, Czech Republic.
Department of Internal Medicine I - Cardiology, University Hospital Olomouc, Czech Republic.

Jiri Stastny (J)

Cardiovascular Center for Adults, Tomas Bata Regional Hospital, Zlin, Czech Republic.

Petr Kopriva (P)

Cardiovascular Center for Adults, Tomas Bata Regional Hospital, Zlin, Czech Republic.

Martin Slabak (M)

Cardiovascular Center for Adults, Tomas Bata Regional Hospital, Zlin, Czech Republic.

Zdenek Coufal (Z)

Cardiovascular Center for Adults, Tomas Bata Regional Hospital, Zlin, Czech Republic.

Jiri Jarkovsky (J)

Institute of Biostatistics and Analyses, Masaryk University, Brno, Czech Republic.

Michal Svoboda (M)

Institute of Biostatistics and Analyses, Masaryk University, Brno, Czech Republic.

Tomas Salek (T)

Department of Clinical Biochemistry, Tomas Bata Regional Hospital, Zlin, Czech Republic.

Lucie Sukupova (L)

Department of the Director, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.

Milos Taborsky (M)

Department of Internal Medicine I - Cardiology, University Hospital Olomouc, Czech Republic.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH